查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1827949

隐球菌病药物市场（按药物类别、最终用户、给药途径、分销管道和患者类型）—2025-2032 年全球预测

Cryptococcosis Treatment Market by Drug Class, End User, Administration Route, Distribution Channel, Patient Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年隐球菌病治疗市场将成长至 125 亿美元，复合年增长率为 6.12%。

主要市场统计数据
基准年2024年 77.7亿美元
预计2025年 82.4亿美元
预测年份：2032年 125亿美元
复合年增长率（%） 6.12%

清晰的策略概述，概括了当今隐球菌病治疗市场的临床复杂性、供应链现实和相关人员的要求

隐球菌病仍然是临床上重要的真菌感染疾病，尤其影响免疫力缺乏的人群，引起了临床医生、采购专业人员和政策制定者的持续关注。有限的有效药物、复杂的给药要求、不断变化的抗药性模式以及合併症管理决定了疾病的治疗前景。因此，相关人员必须将临床最佳实践与现实世界的限制因素（例如药物可及性、给药途径考虑因素以及患者特定因素）相协调。

近年来，医疗体系已转向更具韧性的供应链，并更紧密地衔接医院处方和门诊病人治疗路径。这些转变影响了处方行为和医疗机构的准备情况，尤其是在管理大量HIV感染者和移植患者的机构。因此，决策者面临双重挑战：既要确保患者持续获得第一线治疗和补救性治疗，又要优化不同临床环境下的治疗效果。本引言概述了临床必要性与操作可行性之间的核心矛盾，为后续更详细的分析奠定了基础。

临床创新、供应链重组和管理主导护理如何重新定义隐球菌病药物途径和相关人员的角色

药物治疗的进步、强调抗菌药物管理的监管环境以及全球医药供应链的结构性变化，正在改变隐球菌病的治疗模式。新型抗真菌製剂和改进的脂质体递送系统正在重塑重症疾病的治疗方案，而对抗真菌药物管理的日益重视也正在改善临床医生在住院和门诊的治疗顺序。同时，製造商正在适应价格压力和不断变化的报销模式，这影响了对生产能力和製剂创新的投资。

药物传递和诊断技术的发展正在影响治疗途径。快速诊断和改进的生物标记监测技术使早期发现成为可能，从而可能改变治疗持续时间和强度。在临床创新的同时，卫生系统正在优先考虑供应商多元化和库存弹性，鼓励对本地製造和策略协议的投资。总而言之，这些动态正在为隐球菌病治疗创造一个更细緻入微、临床响应更灵敏的环境，这需要临床团队、供应链经理和商业性相关人员的全面响应。

评估 2025 年关税环境如何加强整个抗真菌供应链的供应链重组、筹资策略和区域製造准备

2025年实施的关税调整的累积影响凸显了现有供应链的脆弱性，并加速了製造商、经销商和医疗保健系统的战略应对。原料药、专用脂质体辅料和成品製​​剂的进口成本不断上升，给采购预算带来了压力，并促使最终用户寻求替代筹资策略。为此，製造商正在重新评估製造地和采购政策，以减轻关税波动的影响并维持关键抗真菌药物的供应。

因此，一些供应商加快了本地化和双重采购力度，投资区域生产基地或增加製造外包以保持供应的连续性。虽然这些措施降低了单一来源风险，但它们需要更多时间进行资本投资、监管部门核准和新设施资格认证。对于采购商而言，关税情况导致对供应商绩效的审查更加严格，并增加使用具有价格稳定机制的长期合约。临床医生和药房负责人也重新评估了他们的库存政策，在即时采购和战略缓衝库存之间取得平衡，以应对短期中断。总体而言，关税环境引发了结构性变化，促使相关人员采取更具弹性（儘管有时成本更高）的方法来确保不间断地获得治疗。

与药物类别、临床环境、给药途径、分销管道和患者类型相关的详细細項分析可区分治疗和获取动态

細項分析揭示了治疗层级、治疗环境、给药途径、分销管道和患者类型之间的不同动态，每种动态对临床实践和商业化都有不同的影响。依药物类别，对Azole、Flucytosine和Polyenes市场进行了研究。在Azole中，进一步探讨了Fluconazole、Posaconazole和Voriconazole等特定药物的市场；而在Polyenes中，重点关注两性Amphotericin B脱氧胆酸盐和Amphotericin B脂质体。这些区别有助于临床选择，因为口服Azole支持长期抑制和门诊管理，而Polyenes和Flucytosine是诱导和升级方案的核心。

目录

第一章 引言

第二章分析方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 脂质体Amphotericin B製剂在改善中枢神经系统渗透的进展。
  • 评估新型三唑衍生物对抗抗药性隐球菌菌株疗效的临床试验
  • 在资源有限的环境中整合快速分子诊断检测以早期检测隐球菌抗原
  • 利用免疫调节剂增强隐球菌病患者宿主反应的新型联合治疗
  • 以长效注射抗霉菌药物提高 HIV 相关隐球菌脑膜炎患者的药物顺从性
  • 人们越来越重视隐球菌抗原进行分散的就地检验，以实现以地区为基础的筛检。
  • 开发一种针对脑内新型隐球菌的奈米粒子药物输送系统
  • 促进创新隐球菌病疗法获得孤儿药认定的监管策略

第六章：美国关税的累积影响（2025年）

第七章：人工智慧（AI）的累积影响（2025年）

8. 隐球菌病药物市场（依药物类别）

  • Azole
    • Fluconazole
    • Posaconazole
    • Voriconazole
  • Flucytosine
  • Polyenes
    • Amphotericin B脱氧胆酸盐
    • 脂质体两性霉素B

9. 隐球菌病药物市场（依最终用户划分）

  • 诊所
    • 门诊
    • 专科诊所
  • 居家护理
  • 医院

第 10 章隐球菌病药物市场（依给药途径）

  • 静脉
    • 中心静脉导管
    • 週边静脉
  • 口服
    • 暂停
    • 药片

第 11 章隐球菌病药物市场（按分销管道）

  • 离线
  • 在线的

第 12 章：隐球菌病药物市场（依患者类型）

  • HIV感染者
  • 未感染爱滋病毒者
    • 正常免疫功能
    • 移植患者

第 13 章：隐球菌病药物市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 14 章。隐球菌病药物市场（按类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章。各国隐球菌病药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 市占率分析（2024年）
  • FPNV定位矩阵（2024年）
  • 竞争分析
    • Pfizer Inc.
    • Gilead Sciences, Inc.
    • Bausch Health Companies Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
    • Astellas Pharma Inc.
    • Cipla Limited
    • Dr. Reddy's Laboratories Ltd.
    • Sun Pharmaceutical Industries Limited
    • Lupin Limited
Product Code: MRR-4316E4E894B8

The Cryptococcosis Treatment Market is projected to grow by USD 12.50 billion at a CAGR of 6.12% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 7.77 billion
Estimated Year [2025] USD 8.24 billion
Forecast Year [2032] USD 12.50 billion
CAGR (%) 6.12%

A clear and strategic overview that frames the clinical complexity, supply chain realities, and stakeholder imperatives shaping cryptococcosis treatment today

Cryptococcosis remains a clinically significant fungal infection that disproportionately affects immunocompromised populations, prompting sustained attention from clinicians, procurement specialists, and policy makers. The therapeutic landscape is shaped by a limited number of efficacious agents, complex administration requirements, and evolving patterns of resistance and co-morbidity management. As a result, stakeholders must reconcile clinical best practices with real-world constraints such as drug availability, route-of-administration considerations, and patient-specific factors.

In recent years, health systems have reoriented toward more resilient supply chains and closer alignment between hospital formularies and outpatient care pathways. These shifts have influenced prescribing behavior and institutional preparedness, especially in settings that manage high volumes of HIV-infected and transplant patients. Consequently, decision-makers face a dual imperative: ensuring uninterrupted access to first-line and salvage therapies while optimizing outcomes across diverse clinical settings. This introduction frames the core tension between clinical necessity and operational feasibility, establishing the foundation for the more detailed analyses that follow.

How clinical innovation, supply chain reconfiguration, and stewardship-driven practices are jointly redefining cryptococcosis therapy pathways and stakeholder roles

The landscape for cryptococcosis treatment is undergoing transformative shifts driven by advances in pharmacotherapy, regulatory emphasis on antimicrobial stewardship, and structural changes in global pharmaceutical supply chains. Newer antifungal formulations and improved liposomal delivery systems have reshaped treatment options for severe disease, while heightened attention to antifungal stewardship is refining how clinicians sequence therapies across inpatient and outpatient settings. At the same time, manufacturers are adapting to pricing pressures and evolving reimbursement models, which influence investment in manufacturing capacity and formulation innovation.

Technological developments in drug delivery and diagnostics are influencing care pathways. Rapid diagnostics and improved biomarker monitoring enable earlier detection and may alter the duration and intensity of therapy, which in turn affects demand dynamics across administration routes. Parallel to clinical innovation, health systems are prioritizing supplier diversification and inventory resilience, prompting investments in local manufacturing and strategic contracting. Taken together, these dynamics are converging to create a more nuanced, clinically responsive environment for cryptococcosis treatment that requires integrated responses across clinical teams, supply chain managers, and commercial stakeholders.

Assessing how the 2025 tariff environment has intensified supply chain realignment, procurement strategies, and regional manufacturing responses across antifungal supply chains

The cumulative impact of tariff adjustments instituted in 2025 has accentuated pre-existing supply chain vulnerabilities and accelerated strategic responses among manufacturers, distributors, and health systems. Higher import costs for active pharmaceutical ingredients, specialized liposomal excipients, and finished drug products have increased pressure on procurement budgets and encouraged end users to seek alternative sourcing strategies. In response, manufacturers have re-evaluated their manufacturing footprints and sourcing policies to mitigate exposure to tariff volatility and to preserve access to critical antifungal agents.

Consequently, some suppliers have accelerated localization and dual-sourcing initiatives, investing in regional production hubs and qualifying additional contract manufacturers to maintain continuity of supply. These actions reduce single-source exposure but require capital expenditure, regulatory approvals, and time to qualify new facilities. For purchasers, the tariff landscape has prompted more stringent supplier performance monitoring and an increased use of long-term agreements with price-stability mechanisms. Clinicians and pharmacy leaders have also revisited inventory policies, balancing just-in-time procurement with strategic buffer stocks to manage short-term disruptions. Overall, the tariff environment has served as a catalyst for structural change, encouraging stakeholders to adopt more resilient, albeit sometimes costlier, approaches to ensuring uninterrupted access to treatment.

In-depth segmentation insights tying drug classes, clinical settings, administration routes, distribution channels, and patient types to differentiated treatment and access dynamics

Segmentation analysis reveals differentiated dynamics across therapeutic classes, care settings, administration routes, distribution channels, and patient types, each of which carries distinct implications for clinical practice and commercialization. Based on drug class, the market is studied across Azoles, Flucytosine, and Polyenes; within Azoles, the landscape is further examined through specific agents such as Fluconazole, Posaconazole, and Voriconazole, while Polyenes merit attention for both Amphotericin B Deoxycholate and Liposomal Amphotericin B formulations. These distinctions inform clinical choice, as oral azoles support long-term suppression and outpatient management, whereas polyene formulations and flucytosine are central to induction and severe disease protocols.

Based on End User, the market is studied across Clinics, Home Care, and Hospitals; Clinics are further differentiated into Outpatient Clinics and Specialist Clinics, reflecting where patients interface with structured monitoring and initiation of therapy. Based on Administration Route, the market is studied across Intravenous and Oral; Intravenous administration is further parsed into Central Line and Peripheral options, while Oral delivery is evaluated by Suspension and Tablet formulations. These nuances affect logistics, nursing resource allocation, and patient adherence strategies. Based on Distribution Channel, the market is studied across Offline and Online, highlighting the growing role of e-commerce and specialty pharmacy channels in improving outpatient access. Finally, based on Patient Type, the market is studied across HIV Infected and Non-HIV Infected populations; Non-HIV Infected groups are further segmented into Immunocompetent and Transplant Patients, each presenting distinct comorbidity profiles and therapeutic risk-benefit calculations. Integrating these segmentation lenses enables a granular understanding of usage patterns, formulary decisions, and the operational trade-offs that guide therapy selection across care settings.

How regional clinical imperatives, regulatory diversity, and manufacturing footprints interact to shape access, procurement, and treatment choices across major global markets

Regional dynamics exert a decisive influence on treatment availability, procurement practices, and clinical management paradigms. In the Americas, policy emphasis on hospital preparedness and the presence of large tertiary care centers shape demand for parenteral induction therapies and influence contract negotiations with manufacturers. Transitioning care from inpatient to outpatient settings is a key priority, and this reshapes how clinicians and pharmacists manage step-down therapy and adherence support.

In Europe, Middle East & Africa, heterogeneous regulatory frameworks and variable health infrastructure create a mosaic of access realities. Countries with advanced diagnostics and reimbursement pathways have adopted newer formulations more rapidly, while resource-constrained settings prioritize cost-effective, readily available agents and pragmatic protocols that account for limited inpatient capacity. Cross-border procurement and donor-supported supply channels remain important in many jurisdictions. In the Asia-Pacific region, manufacturing capacity, particularly for generic azoles and certain APIs, is concentrated in a handful of producer countries, influencing regional supply dynamics and pricing. At the same time, several health systems are investing in diagnostic capacity and regional distribution networks to improve early detection and outpatient continuity of care. These regional patterns highlight the need for strategies tailored to local regulatory, clinical, and supply-chain contexts, while acknowledging the transnational nature of manufacturing and distribution interdependencies.

Competitive positioning and capability analysis of manufacturers, distributors, and service providers that are reshaping therapeutic access and clinical adoption in cryptococcosis care

Key companies operating in this therapeutic area are differentiated by their capabilities in formulation expertise, sterile manufacturing, global distribution networks, and regulatory compliance. Some manufacturers have invested heavily in liposomal formulation technology to improve tolerability and reduce nephrotoxicity, which has implications for uptake in intensive care and transplant units. Other firms have differentiated through robust generics portfolios and extensive API sourcing arrangements that support cost-competitive supply to outpatient and resource-constrained settings.

Distributors and specialty pharmacies play a pivotal role in bridging hospital and community care, particularly where complex intravenous therapies transition to home infusion or ambulatory infusion centers. Clinical service providers and contract manufacturers that can ensure consistent quality, scalable production, and accelerated regulatory filing pathways are increasingly valuable partners. In addition, diagnostic and digital health firms that enable earlier detection and remote monitoring contribute to more efficient treatment pathways. Overall, organizational strength is defined by the ability to integrate clinical evidence, manufacturing reliability, and responsive commercial models to support both acute-care induction and long-term suppression strategies across diverse patient populations.

Actionable strategic recommendations for leaders to strengthen supply resilience, align portfolios with clinical pathways, and optimize commercialization across care transitions

Industry leaders should prioritize a set of actionable strategies that align clinical priorities with resilient supply and adaptive commercial models. First, investing in manufacturing dual-sourcing and regional production capacity will reduce single-source risk and mitigate trade-related volatility. Second, aligning product portfolios with care pathway requirements-such as ensuring availability of both intravenous induction options and oral consolidation therapies-will support continuity across inpatient and outpatient settings. Third, strengthening partnerships with specialty pharmacies and home-infusion providers will facilitate safe transitions of care and improve adherence for long-term suppression regimens.

Moreover, leaders should embed robust stewardship and diagnostics into their commercialization plans to support appropriate use and to protect clinical efficacy. Contracting strategies that include price-stability clauses, inventory sharing arrangements, and outcomes-linked agreements can stabilize procurement budgets while maintaining access. Finally, targeted investments in clinician education, formulary support, and patient adherence programs will accelerate uptake in appropriate settings and improve outcomes. Collectively, these recommendations provide a pragmatic blueprint for converting strategic insight into operational resilience and improved patient care.

A transparent mixed-methods research approach combining clinician and supply-chain interviews with regulatory and technical literature to validate actionable insights

This research synthesizes primary and secondary inputs to produce a comprehensive understanding of clinical practice, supply-chain dynamics, and commercial behaviors. Primary research included structured interviews with clinicians, pharmacy directors, procurement officers, and manufacturing and distribution executives to capture real-world operational challenges, therapeutic decision drivers, and procurement practices. These qualitative insights were supplemented by secondary analysis of peer-reviewed clinical literature, regulatory guidance, product labels, and public-domain manufacturing and trade data to ensure technical accuracy and contextual depth.

Triangulation methods were applied to reconcile divergent perspectives and to validate recurring patterns across geographies and care settings. Where appropriate, regulatory timelines and manufacturing capacity constraints were mapped against clinical treatment protocols to identify potential bottlenecks and points of intervention. The methodology prioritized transparency in assumptions and robustness in cross-validation to ensure that conclusions reflect observable trends and expert judgment rather than speculative projection.

A concise synthesis emphasizing coordinated action across manufacturing, clinical, and procurement stakeholders to secure treatment access and optimize patient outcomes

In summary, cryptococcosis treatment is situated at the intersection of clinical complexity and operational fragility, requiring coordinated action across manufacturers, health systems, and clinical teams. Therapeutic choices hinge on drug class selection, administration route feasibility, and patient-specific factors, while access is shaped by regional manufacturing footprints, procurement strategies, and evolving trade policies. The cumulative pressures from tariff shifts and supply-chain realignments underscore the necessity of proactive risk management, including diversified sourcing and closer integration between inpatient and outpatient care channels.

Looking ahead, organizations that invest in resilient manufacturing, targeted clinical education, robust stewardship, and strategic partnerships will be best positioned to sustain access and improve clinical outcomes. By translating analytical insight into pragmatic interventions-ranging from contracting innovations to diagnostic-enabled care pathways-stakeholders can navigate the complex landscape more effectively and ensure that patients receive timely, evidence-based therapy.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in liposomal amphotericin B formulations to improve central nervous system penetration
  • 5.2. Clinical trials evaluating the efficacy of novel triazole derivatives against resistant Cryptococcus strains
  • 5.3. Integration of rapid molecular diagnostic assays for early detection of cryptococcal antigen in resource limited settings
  • 5.4. Emerging combination therapies leveraging immunomodulators to enhance host response in cryptococcosis patients
  • 5.5. Adoption of long acting injectable antifungal agents to improve adherence in HIV associated cryptococcal meningitis
  • 5.6. Increasing focus on decentralized point of care testing for cryptococcal antigen to enable community based screening
  • 5.7. Development of nanoparticle based drug delivery systems to target Cryptococcus neoformans in the brain
  • 5.8. Regulatory strategies accelerating orphan drug designation for innovative cryptococcosis therapies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cryptococcosis Treatment Market, by Drug Class

  • 8.1. Azoles
    • 8.1.1. Fluconazole
    • 8.1.2. Posaconazole
    • 8.1.3. Voriconazole
  • 8.2. Flucytosine
  • 8.3. Polyenes
    • 8.3.1. Amphotericin B Deoxycholate
    • 8.3.2. Liposomal Amphotericin B

9. Cryptococcosis Treatment Market, by End User

  • 9.1. Clinics
    • 9.1.1. Outpatient Clinics
    • 9.1.2. Specialist Clinics
  • 9.2. Home Care
  • 9.3. Hospitals

10. Cryptococcosis Treatment Market, by Administration Route

  • 10.1. Intravenous
    • 10.1.1. Central Line
    • 10.1.2. Peripheral
  • 10.2. Oral
    • 10.2.1. Suspension
    • 10.2.2. Tablet

11. Cryptococcosis Treatment Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Cryptococcosis Treatment Market, by Patient Type

  • 12.1. HIV Infected
  • 12.2. Non-HIV Infected
    • 12.2.1. Immunocompetent
    • 12.2.2. Transplant Patients

13. Cryptococcosis Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cryptococcosis Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cryptococcosis Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Pfizer Inc.
    • 16.3.2. Gilead Sciences, Inc.
    • 16.3.3. Bausch Health Companies Inc.
    • 16.3.4. Teva Pharmaceutical Industries Ltd.
    • 16.3.5. Viatris Inc.
    • 16.3.6. Astellas Pharma Inc.
    • 16.3.7. Cipla Limited
    • 16.3.8. Dr. Reddy's Laboratories Ltd.
    • 16.3.9. Sun Pharmaceutical Industries Limited
    • 16.3.10. Lupin Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CRYPTOCOCCOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CRYPTOCOCCOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CRYPTOCOCCOSIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POSACONAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POSACONAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POSACONAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POSACONAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POSACONAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POSACONAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY VORICONAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY VORICONAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY VORICONAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY VORICONAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY VORICONAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY VORICONAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCYTOSINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCYTOSINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCYTOSINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCYTOSINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCYTOSINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY FLUCYTOSINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AMPHOTERICIN B DEOXYCHOLATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AMPHOTERICIN B DEOXYCHOLATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AMPHOTERICIN B DEOXYCHOLATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AMPHOTERICIN B DEOXYCHOLATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AMPHOTERICIN B DEOXYCHOLATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AMPHOTERICIN B DEOXYCHOLATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY LIPOSOMAL AMPHOTERICIN B, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY LIPOSOMAL AMPHOTERICIN B, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY LIPOSOMAL AMPHOTERICIN B, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY LIPOSOMAL AMPHOTERICIN B, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY LIPOSOMAL AMPHOTERICIN B, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY LIPOSOMAL AMPHOTERICIN B, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SPECIALIST CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SPECIALIST CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SPECIALIST CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SPECIALIST CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SPECIALIST CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SPECIALIST CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CENTRAL LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CENTRAL LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CENTRAL LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CENTRAL LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CENTRAL LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CENTRAL LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PERIPHERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PERIPHERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PERIPHERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PERIPHERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PERIPHERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PERIPHERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SUSPENSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SUSPENSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OFFLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY OFFLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HIV INFECTED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HIV INFECTED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HIV INFECTED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HIV INFECTED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HIV INFECTED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY HIV INFECTED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPETENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPETENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPETENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPETENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPETENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY IMMUNOCOMPETENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TRANSPLANT PATIENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TRANSPLANT PATIENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TRANSPLANT PATIENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TRANSPLANT PATIENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TRANSPLANT PATIENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY TRANSPLANT PATIENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY NON-HIV INFECTED, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 302. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 304. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY POLYENES, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 310. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
  • TABLE 314. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY INTRAVENOUS, 2025-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST CRYPTOCOCCOSIS TREATMENT MARKET SIZE, BY ORAL, 2018-2024 (USD MILL